The clinical trials below are available in the specialty you selected. Choose a different specialty.

Study of PEG-rIL-29 Administered in Combination with Ribavirin for Untreated Hepatitis C Patients
Patients with hepatitis C are needed for a trial to study the safety and effectiveness of different doses of PEG-rIL-29 when given with the standard dose of ribavirin, compared to the standard dose of peginterferon alfa-2a (PEGASYS®) given with ribavirin. (REF# 20033)

Nonalcoholic Fatty Liver Disease (NAFLD) Adult Database 2
Adults with nonalcoholic fatty liver disease are needed to participate in an observational study. (REF# 20074)

Continuous Interferon Delivery via the Medtronic Paradigm® Pump Infusion
People with the hepatitis C virus are needed for a clinical trial examining continuous interferon delivery with the Medtronic Paradigm Pump. (REF# 18025)

Study of Acid Reflux in Children with Asthma
Physicians at the Duke Asthma Clinical Research Center (ACRC) are studying acid reflux (GER) and asthma in children. (REF# 0739)

Metformin for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD)
Patients with non-alcoholic fatty liver disease are needed for this study. (REF# 6196)

Trial of CTS-1027 in Interferon-Naïve Hepatitis C Patients
Hepatitis C patients who are not suitable for interferon-based HCV treatment are needed for a clinical study (REF# 17427)

Aprepitant for Prevention of Post-ERCP Pancreatitis
A trial to determine if the administration of aprepitant will prevent the development of post-ERCP pancreatitis and abdominal pain. (REF# 9533)

Hepatitis Alcohol Reduction Team (Hep ART)
If you have hepatitis C and consume alcohol of any kind, you may be eligible to participate in this study. (REF# 9188)

A Phase 3 Safety and Efficacy Study of Boceprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin Protocol No: P05685
This study assesses if subjects infected with hepatitis C virus (HCV) genotype 1 who receive a new investigational drug called boceprevir together with standard therapy [peginterferon alfa-2a (PEG2a) and ribavirin] get a better response rate than with standard therapy alone. (REF# 13987)

Telaprevir in Hepatitis C Patients That Failed Previous Standard Treatment (VX-950-TiDP24-C216)
The purpose of this study is to investigate whether or not telaprevir combined with Pegasys® and Copegus® will be more effective in decreasing viral load than the standard treatment alone for subjects with chronic genotype 1 hepatitis C infections who were not cured after a previous standard therapy for HCV. (REF# 11768)

Page 1 2 of 2